Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study.
major depressive disorder
transcranial pulsed electromagnetic fields
treatment-resistant depression
Journal
European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820
Informations de publication
Date de publication:
18 02 2020
18 02 2020
Historique:
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
1
1
2021
Statut:
epublish
Résumé
The efficacy of antidepressant treatment is fair, but the efficacy is considerably lower in patients failing two or more trials underscoring the need for new treatment options. Our study evaluated the augmenting antidepressant effect of 8-weeks transcranial pulsed electromagnetic field (T-PEMF) therapy in patients with treatment-resistant depression. A multicenter 8-week single-arm cohort study conducted by the Danish University Antidepressant Group. In total, 58 participants (20 men and 38 women) with a moderate to severe depression as part of a depressive disorder according to ICD-10 who fulfilled criteria for treatment resistance were included, with 19 participants being nonresponders to electroconvulsive therapy during the current depressive episode. Fifty-two participants completed the study period. Scores on the Hamilton Depression Scale 17-items version (HAM-D17) decreased significantly from baseline (mean = 20.6, SD 4.0) to endpoint (mean = 12.6, SD 7.1; N = 58). At endpoint, utilizing a Last Observation Carried Forward analysis, 49 and 28% of those participants with, respectively, a nonchronic current episode (≤2 years; N = 33) and a chronic current episode (>2 years; N = 25) were responders, that is, achieved a reduction of 50% or more on the HAM-D17 scale. At endpoint, respectively, 30 and 16% obtained remission, defined as HAM-D17 ≤ 7. On the Hamilton Scale 6-item version (HAM-D6), respectively, 51 and 16% obtained remission, defined as HAM-D6 ≤ 4. The findings indicate a potential beneficial role of T-PEMF therapy as an augmentation treatment to ongoing pharmacotherapy in treatment-resistant depression.
Sections du résumé
BACKGROUND
The efficacy of antidepressant treatment is fair, but the efficacy is considerably lower in patients failing two or more trials underscoring the need for new treatment options. Our study evaluated the augmenting antidepressant effect of 8-weeks transcranial pulsed electromagnetic field (T-PEMF) therapy in patients with treatment-resistant depression.
METHODS
A multicenter 8-week single-arm cohort study conducted by the Danish University Antidepressant Group.
RESULTS
In total, 58 participants (20 men and 38 women) with a moderate to severe depression as part of a depressive disorder according to ICD-10 who fulfilled criteria for treatment resistance were included, with 19 participants being nonresponders to electroconvulsive therapy during the current depressive episode. Fifty-two participants completed the study period. Scores on the Hamilton Depression Scale 17-items version (HAM-D17) decreased significantly from baseline (mean = 20.6, SD 4.0) to endpoint (mean = 12.6, SD 7.1; N = 58). At endpoint, utilizing a Last Observation Carried Forward analysis, 49 and 28% of those participants with, respectively, a nonchronic current episode (≤2 years; N = 33) and a chronic current episode (>2 years; N = 25) were responders, that is, achieved a reduction of 50% or more on the HAM-D17 scale. At endpoint, respectively, 30 and 16% obtained remission, defined as HAM-D17 ≤ 7. On the Hamilton Scale 6-item version (HAM-D6), respectively, 51 and 16% obtained remission, defined as HAM-D6 ≤ 4.
CONCLUSIONS
The findings indicate a potential beneficial role of T-PEMF therapy as an augmentation treatment to ongoing pharmacotherapy in treatment-resistant depression.
Identifiants
pubmed: 32093804
doi: 10.1192/j.eurpsy.2020.3
pii: S0924933820000036
pmc: PMC7315871
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Clinical Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18Références
Acta Neuropsychiatr. 2014 Oct;26(5):261-3
pubmed: 25371922
World Psychiatry. 2015 Oct;14(3):309-10
pubmed: 26407785
Psychiatry Res. 2016 Jun 30;240:421-430
pubmed: 27155594
Acta Neuropsychiatr. 2015 Apr;27(2):119-25
pubmed: 25582756
J Clin Psychiatry. 2015 Oct;76(10):1374-84
pubmed: 26528644
J Clin Psychiatry. 2006 May;67(5):688-95
pubmed: 16841617
J Clin Psychiatry. 2001;62 Suppl 16:26-31
pubmed: 11480881
Pharmacopsychiatry. 2008 Mar;41(2):41-7
pubmed: 18311683
Acta Neuropsychiatr. 2014 Oct;26(5):272-9
pubmed: 25241755
Clin Psychopharmacol Neurosci. 2017 Aug 31;15(3):210-221
pubmed: 28783929
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Psychother Psychosom. 2017;86(3):141-149
pubmed: 28490031
Int Psychogeriatr. 2018 Jun;30(6):833-841
pubmed: 29380713
J Clin Psychiatry. 2001;62 Suppl 16:10-7
pubmed: 11480879
Acta Psychiatr Scand Suppl. 1986;326:1-37
pubmed: 3458353
Biol Psychiatry. 2010 Jul 15;68(2):163-9
pubmed: 20385376
Depress Anxiety. 2016 Aug;33(8):746-53
pubmed: 27059158
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 3;51:181-9
pubmed: 24556538
Int J Neuropsychopharmacol. 2013 Apr;16(3):501-6
pubmed: 23174090